NCT05649618View on ClinicalTrials.gov

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2026

Conditions
Solid Tumor
Interventions
BIOLOGICAL

Tumor Infiltrating Lymphocytes

On day 0 patients will be intravenous infusion of TILs

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regimen

DRUG

Cyclophosphamide Capsules

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

IL-2

Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV